Skip to main content
Top
Published in: Diabetologia 8/2010

01-08-2010 | Article

Cardiovascular disease risk factors, depression symptoms and antidepressant medicine use in the Look AHEAD (Action for Health in Diabetes) clinical trial of weight loss in diabetes

Authors: R. R. Rubin, S. A. Gaussoin, M. Peyrot, V. DiLillo, K. Miller, T. A. Wadden, D. S. West, R. R. Wing, W. C. Knowler, for the Look AHEAD Research Group

Published in: Diabetologia | Issue 8/2010

Login to get access

Abstract

Aims/hypothesis

To determine the associations of baseline depression symptoms and use of antidepressant medicines (ADMs) with baseline cardiovascular disease (CVD) risk factors in Look AHEAD (Action for Health in Diabetes) trial participants.

Methods

Look AHEAD participants (n = 5,145; age 58.7 ± 6.8 years; BMI 35.8 ± 5.8 kg/m2) were assessed for CVD risk factors (elevated HbA1c or insulin use, elevated BP or antihypertensive use, elevated lipid levels or lipid-lowering medication, current smoking, BMI ≥30 kg/m2, lower peak exercise capacity assessed as metabolic equivalents [METs], and ankle–brachial index <0.9 or >1.3). Participants also completed the Beck Depression Inventory (BDI) and reported their use of ADMs.

Results

Of the participants, 14.7% had BDI scores ≥11, consistent with mild-moderate depression, and 16.5% took ADMs; 4.4% had both depression markers (i.e. elevated symptom scores and took ADMs). In logistic regression analyses of CVD risk (elevated risk factor or use of medication to control the risk factor), controlled for demographic factors, continuous BDI scores and ADM use were each independently associated with elevated BP (or medication), current smoking, BMI ≥30 kg/m2 and lower MET values. ADM use was also associated with elevated serum lipids or use of lipid-lowering medication.

Conclusions/interpretation

Among Look AHEAD participants, depression symptoms or ADM use on entry to the study were each independently associated with a wide range of CVD risk factors. Future research should assess the temporal dynamics of the relationships of depression symptoms and ADM use with CVD risk factors.

Trial registration

Clinicaltrials.gov NCT00017953

Funding

This study is funded by the National Institutes of Health with additional support from the Centers for Disease Control and Prevention.
Appendix
Available only for authorised users
Literature
1.
go back to reference Egede LE, Nietert PJ, Zheng D (2005) Depression and all-cause and coronary heart disease mortality among adults with and without diabetes. Diab Care 28:1339–1345CrossRef Egede LE, Nietert PJ, Zheng D (2005) Depression and all-cause and coronary heart disease mortality among adults with and without diabetes. Diab Care 28:1339–1345CrossRef
2.
go back to reference Egede LE, Zheng D (2003) Independent factors associated with major depressive disorder in a national sample. Diab Care 26:104–111CrossRef Egede LE, Zheng D (2003) Independent factors associated with major depressive disorder in a national sample. Diab Care 26:104–111CrossRef
3.
go back to reference Lett H, Blumenthal JA, Babyak M, Sherwood A, Strauman T, Robins C (2004) Depression as a risk factor for coronary artery disease: evidence, mechanisms, and treatment. Psychosom Med 66:305–315CrossRefPubMed Lett H, Blumenthal JA, Babyak M, Sherwood A, Strauman T, Robins C (2004) Depression as a risk factor for coronary artery disease: evidence, mechanisms, and treatment. Psychosom Med 66:305–315CrossRefPubMed
4.
go back to reference Van Melle JP, de Jong P, Spijkerman TA et al (2004) Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis. Psychosom Med 66:814–822CrossRefPubMed Van Melle JP, de Jong P, Spijkerman TA et al (2004) Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis. Psychosom Med 66:814–822CrossRefPubMed
5.
go back to reference Cohen HW, Gibson G, Alderman MH (2000) Excess risk of myocardial infarction in patients treated with antidepressant medications: association with tricyclic agents. Am J Med 108:2–8CrossRefPubMed Cohen HW, Gibson G, Alderman MH (2000) Excess risk of myocardial infarction in patients treated with antidepressant medications: association with tricyclic agents. Am J Med 108:2–8CrossRefPubMed
6.
go back to reference Taylor CB, Youngblood ME, Catellier D, for the ENRICHD Investigators et al (2005) Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry 62:792–798CrossRefPubMed Taylor CB, Youngblood ME, Catellier D, for the ENRICHD Investigators et al (2005) Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry 62:792–798CrossRefPubMed
7.
go back to reference Thombs BD, de Jonge P, Coyne JC et al (2008) Depression screening and patient outcomes in cardiovascular care: a systematic review. JAMA 300:2161–2171CrossRefPubMed Thombs BD, de Jonge P, Coyne JC et al (2008) Depression screening and patient outcomes in cardiovascular care: a systematic review. JAMA 300:2161–2171CrossRefPubMed
8.
go back to reference Rubin RR, Ma Y, Marrero DG, for the Diabetes Prevention Program Research Group et al (2008) Elevated depression symptoms, antidepressant medicine use, and risk of developing diabetes during the Diabetes Prevention Program. Diab Care 31:420–426CrossRef Rubin RR, Ma Y, Marrero DG, for the Diabetes Prevention Program Research Group et al (2008) Elevated depression symptoms, antidepressant medicine use, and risk of developing diabetes during the Diabetes Prevention Program. Diab Care 31:420–426CrossRef
9.
go back to reference Ryan DH, Espeland MA et al (2003) Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials 24:610–628CrossRefPubMed Ryan DH, Espeland MA et al (2003) Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials 24:610–628CrossRefPubMed
10.
go back to reference Lange S, Trampisch HJ, Haberi R et al (2005) Excess 1-year cardiovascular risk in elderly primary care patients with a low ankle–brachial index (ABI) and high homocysteine level. Atherosclerosis 178:351–357CrossRefPubMed Lange S, Trampisch HJ, Haberi R et al (2005) Excess 1-year cardiovascular risk in elderly primary care patients with a low ankle–brachial index (ABI) and high homocysteine level. Atherosclerosis 178:351–357CrossRefPubMed
11.
go back to reference Ribisl PM, Lang W, Jaramillo SA, for the Look AHEAD Research Group et al (2007) Exercise capacity and cardiovascular/metabolic characteristics of overweight and obese individuals with type 2 diabetes: the Look AHEAD clinical trial. Diab Care 30:2679–2684CrossRef Ribisl PM, Lang W, Jaramillo SA, for the Look AHEAD Research Group et al (2007) Exercise capacity and cardiovascular/metabolic characteristics of overweight and obese individuals with type 2 diabetes: the Look AHEAD clinical trial. Diab Care 30:2679–2684CrossRef
12.
go back to reference The Look AHEAD Research Group (2006) Baseline characteristics of the randomized cohort for the Look AHEAD (Action for Health in Diabetes) Study. Vasc Dis Res 3:202–215CrossRef The Look AHEAD Research Group (2006) Baseline characteristics of the randomized cohort for the Look AHEAD (Action for Health in Diabetes) Study. Vasc Dis Res 3:202–215CrossRef
13.
go back to reference Beck AT, Steers RA (1993) Manual of the Beck Depression Inventory. Psychological Corporation, San Antonio, TX Beck AT, Steers RA (1993) Manual of the Beck Depression Inventory. Psychological Corporation, San Antonio, TX
14.
go back to reference Rubin RR, Knowler WC, Ma Y et al (2005) Depression symptoms and antidepressant medicine use in Diabetes Prevention Program participants. Diab Care 28:830–837CrossRef Rubin RR, Knowler WC, Ma Y et al (2005) Depression symptoms and antidepressant medicine use in Diabetes Prevention Program participants. Diab Care 28:830–837CrossRef
15.
go back to reference Norman GR, Sloan JA, Wyrich KW (2003) Interpretation of changes in health-related quality of life: the remarkable universality of a half standard. Med Care 41:582–592CrossRefPubMed Norman GR, Sloan JA, Wyrich KW (2003) Interpretation of changes in health-related quality of life: the remarkable universality of a half standard. Med Care 41:582–592CrossRefPubMed
16.
go back to reference McDermott MM, Liu K, Criqui MH et al (2005) Ankle–brachial index and subclinical cardiac and carotid disease: the multi-ethnic study of atherosclerosis. Am J Epidemiol 162:33–41CrossRefPubMed McDermott MM, Liu K, Criqui MH et al (2005) Ankle–brachial index and subclinical cardiac and carotid disease: the multi-ethnic study of atherosclerosis. Am J Epidemiol 162:33–41CrossRefPubMed
17.
go back to reference American Diabetes Association (2005) Standards of medical care in diabetes. Diab Care 28(Suppl 1):S4–S36CrossRef American Diabetes Association (2005) Standards of medical care in diabetes. Diab Care 28(Suppl 1):S4–S36CrossRef
18.
go back to reference Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486–2497 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486–2497
19.
go back to reference Giorda CB, Avogaro A, Maggini M, for the Diabetes Informatics Study Group (2008) Recurrence of vascular events in patients with type 2 diabetes: epidemiology and risk factors. Diab Care 31:2154–2159CrossRef Giorda CB, Avogaro A, Maggini M, for the Diabetes Informatics Study Group (2008) Recurrence of vascular events in patients with type 2 diabetes: epidemiology and risk factors. Diab Care 31:2154–2159CrossRef
20.
go back to reference Cederholm J, Eeg-Olofsson K, Eliasson B, Zethelius B, Nilsson PM, Gudbjornsdottir S, on behalf of the Swedish National Diabetes Register (2008) Risk prediction of cardiovascular disease in type 2 diabetes: a risk equation from the Swedish National Diabetes Register. Diab Care 31:2038–2043CrossRef Cederholm J, Eeg-Olofsson K, Eliasson B, Zethelius B, Nilsson PM, Gudbjornsdottir S, on behalf of the Swedish National Diabetes Register (2008) Risk prediction of cardiovascular disease in type 2 diabetes: a risk equation from the Swedish National Diabetes Register. Diab Care 31:2038–2043CrossRef
21.
go back to reference Gonzalez JS, Safren SA, Cagliero E et al (2007) Depression, self-care, and medication adherence in type 2 diabetes: relationships across the full range of symptom severity. Diab Care 30:2222–2227CrossRef Gonzalez JS, Safren SA, Cagliero E et al (2007) Depression, self-care, and medication adherence in type 2 diabetes: relationships across the full range of symptom severity. Diab Care 30:2222–2227CrossRef
22.
go back to reference Penninix BW, Beelman AT, Honig A et al (2001) Depression and cardiac mortality: results from a community-based longitudinal study. Arch Gen Psychiatry 58:229–230CrossRef Penninix BW, Beelman AT, Honig A et al (2001) Depression and cardiac mortality: results from a community-based longitudinal study. Arch Gen Psychiatry 58:229–230CrossRef
23.
go back to reference Physicians Desk Reference, 22nd edn. (2008) Thomson, Montvale, NJ Physicians Desk Reference, 22nd edn. (2008) Thomson, Montvale, NJ
24.
go back to reference Jiang W, O’Connor C, Silva SG, for the SADHART-CF Investigators et al (2008) Safety and Efficacy of Sertraline for Depression in Patients with CHF (SADHART-CHF): a randomized, double-blind, placebo-controlled trial of sertraline for major depression with congestive heart failure. Am Heart J 156:437–444CrossRefPubMed Jiang W, O’Connor C, Silva SG, for the SADHART-CF Investigators et al (2008) Safety and Efficacy of Sertraline for Depression in Patients with CHF (SADHART-CHF): a randomized, double-blind, placebo-controlled trial of sertraline for major depression with congestive heart failure. Am Heart J 156:437–444CrossRefPubMed
Metadata
Title
Cardiovascular disease risk factors, depression symptoms and antidepressant medicine use in the Look AHEAD (Action for Health in Diabetes) clinical trial of weight loss in diabetes
Authors
R. R. Rubin
S. A. Gaussoin
M. Peyrot
V. DiLillo
K. Miller
T. A. Wadden
D. S. West
R. R. Wing
W. C. Knowler
for the Look AHEAD Research Group
Publication date
01-08-2010
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 8/2010
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-010-1765-1

Other articles of this Issue 8/2010

Diabetologia 8/2010 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.